The Foundation of Tomorrow's Most Enduring Companies
We concentrate our capital at the intersection of technology and healthcare, backing founders who are redefining what is possible in medicine and life sciences.
Connected care platforms, remote patient monitoring, and digital therapeutics extending clinical reach beyond traditional hospital walls.
Next-generation biologics, gene therapy, precision oncology, and novel drug discovery platforms with strong intellectual property moats.
Software-enabled diagnostic devices, minimally invasive surgical systems, and implantable technology improving patient outcomes at scale.
Clinical decision support, radiology AI, accelerated drug discovery, and administrative automation for healthcare systems and payers.
Curevstone Capital partners with exceptional founders at the earliest and most critical stages of company formation. We believe that enduring companies are not merely built — they are founded on deep insight, technical courage, and the will to reimagine entire industries.
Our name reflects our core conviction: the most important investment is the first one — the cornerstone that determines whether a company will stand for a decade or crumble within a year. We provide $5M Seed Round capital alongside operational guidance, network access, and long-term partnership that goes far beyond a wire transfer.
We look for founders who possess both the vision to see what others cannot and the resilience to build through what others will not endure.
Our Full Story
We concentrate our $5M seed investments in sectors where technology-driven disruption is inevitable, founders are visionary, and the market opportunity is global from day one.
Foundation models, applied AI, autonomous systems, and AI-native enterprise software redefining how work gets done.
Semiconductor innovation, quantum computing, advanced materials, and hard science translated into commercial opportunity.
Tools, platforms, and APIs that raise the productivity floor for every software engineer building the next generation of products.
Technologies that decarbonize transportation, industrials, and energy production while delivering compelling unit economics.
Genomics, precision medicine, digital therapeutics, and diagnostics platforms that extend healthy human lifespan.
Next-generation financial infrastructure, digital assets, and compliance automation for the global digital economy.
We believe in rapid, respectful engagement. Within 72 hours of receiving a deck, our team forms a preliminary view. We commit to an initial call within two weeks — no ghost rounds, no artificial delays. Founders deserve honesty about where we stand.
Our diligence is thorough but time-boxed. We conduct technical review, reference calls with domain experts, market-sizing analysis, and competitive landscape mapping. We share our findings with founders — because transparency builds better partnerships from the start.
When we commit, we commit decisively. Our standard Seed Round is $5M. We move from signed term sheet to wire in under 30 days. We lead rounds, co-invest with trusted partners, and help founders fill out their cap table with the right strategic angels.
Post-investment, we work alongside the founding team on hiring strategy, go-to-market sequencing, growth-round preparation, and board best practices. Our portfolio network spans hundreds of operators, advisors, and follow-on investors across four continents.
Enterprise AI orchestration platform that deploys, monitors, and governs multi-model workflows at production scale.
Secrets management and credential rotation infrastructure for cloud-native teams operating across hybrid environments.
AI-guided drug discovery platform targeting rare oncology indications with a pipeline of five clinical-stage candidates.
Long-duration iron-air battery systems designed for grid-scale energy storage in industrial and utility markets.
Embedded treasury and working capital platform that gives mid-market companies CFO-grade financial visibility and control.
Photonic quantum computing startup building reconfigurable optical chips that reduce error rates by an order of magnitude.
"Curevstone was the first check in our seed round at a time when the market was uncertain. They moved decisively, led on structure, and have been invaluable board partners ever since. They operate like co-founders — not just investors."
"What distinguishes Curevstone from every other fund we spoke to is that they genuinely understand the technology. During diligence they asked questions no other investor asked. That technical depth translates directly into better portfolio support."
"We raised our $5M seed in 22 days from first meeting to wire. Curevstone ran a tight, professional process and introduced us to three other investors who joined the round. They operate at a level of integrity that is rare in early-stage venture."
A detailed breakdown of how seed rounds are structured today — valuations, dilution, convertible instruments, and what founders should negotiate for.
Building a company around AI models is fundamentally different from traditional SaaS. We outline what founders need to get right from day one.
Curevstone Capital's investment thesis: why we back health technology at the seed stage, and why the next decade belongs to founders solving the hardest problems in medicine.
Portfolio Co-Funded Alongside
New Enterprise Associates
We invest $5M seed rounds in exceptional founders with the conviction and capability to build companies that last. If that is you, we want to hear from you.
Portfolio Companies Featured In
